Invention Grant
US08822539B2 Combination therapies: inhibitors of GABA transaminase and NKCC1
有权
联合疗法：GABA转氨酶和NKCC1抑制剂
- Patent Title: Combination therapies: inhibitors of GABA transaminase and NKCC1
- Patent Title (中): 联合疗法：GABA转氨酶和NKCC1抑制剂
-
Application No.: US13069311Application Date: 2011-03-22
-
Publication No.: US08822539B2Publication Date: 2014-09-02
- Inventor: Frances E. Jensen
- Applicant: Frances E. Jensen
- Applicant Address: US MA Boston
- Assignee: Children's Medical Center Corporation
- Current Assignee: Children's Medical Center Corporation
- Current Assignee Address: US MA Boston
- Agency: Fish & Richardson P.C.
- Main IPC: A01N41/06
- IPC: A01N41/06 ; A61K31/08 ; A01N37/00 ; A61K31/19 ; C07C303/00 ; C07C307/00 ; C07C309/00 ; C07C311/00 ; C07C61/00 ; C07C61/08
Abstract:
Inhibitors of NKCC1, such as bumetanide, when coadministered with inhibitors of GABA transaminase, such as vigabatrin, attenuate both the retinal toxicity and the intramyelinic edema.
Public/Granted literature
- US20110237554A1 Combination therapies: inhibitors of GABA transaminase and NKCC1 Public/Granted day:2011-09-29
Information query
